SEK 0.75
(-3.1%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 58.5 Million SEK | 17.71% |
2022 | 49.7 Million SEK | -21.35% |
2021 | 63.19 Million SEK | 33.61% |
2020 | 47.29 Million SEK | -15.51% |
2019 | 55.98 Million SEK | 105.09% |
2018 | 27.29 Million SEK | -13.32% |
2017 | 31.49 Million SEK | 30.26% |
2016 | 24.17 Million SEK | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 53.87 Million SEK | 14.49% |
2024 Q1 | 47.05 Million SEK | -19.57% |
2023 Q3 | 43.75 Million SEK | 6.51% |
2023 Q4 | 58.5 Million SEK | 33.71% |
2023 FY | 58.5 Million SEK | 17.71% |
2023 Q2 | 41.08 Million SEK | -8.14% |
2023 Q1 | 44.72 Million SEK | -10.02% |
2022 Q3 | 51.93 Million SEK | -5.68% |
2022 Q4 | 49.7 Million SEK | -4.3% |
2022 Q2 | 55.06 Million SEK | -7.12% |
2022 Q1 | 59.28 Million SEK | -6.18% |
2021 Q4 | 63.19 Million SEK | 58.14% |
2021 Q3 | 39.96 Million SEK | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
AlzeCure Pharma AB (publ) | 32 Million SEK | -82.829% |
BioGaia AB (publ) | 2.33 Billion SEK | 97.492% |
Enzymatica AB (publ) | 125.91 Million SEK | 53.533% |
Enorama Pharma AB (publ) | 34.38 Million SEK | -70.153% |
Gabather AB (publ) | 2.93 Million SEK | -1892.067% |
Klaria Pharma Holding AB (publ.) | 73.12 Million SEK | 19.985% |
Moberg Pharma AB (publ) | 634.73 Million SEK | 90.782% |
Nanexa AB (publ) | 132.25 Million SEK | 55.763% |
Newbury Pharmaceuticals AB (publ) | 90.87 Million SEK | 35.615% |
ODI Pharma AB | 12.27 Million SEK | -376.636% |
Orexo AB (publ) | 786.6 Million SEK | 92.562% |
Probi AB (publ) | 1.55 Billion SEK | 96.226% |
Swedencare AB (publ) | 9.52 Billion SEK | 99.386% |
Swedish Orphan Biovitrum AB (publ) | 74.02 Billion SEK | 99.921% |
Toleranzia AB | 160.42 Million SEK | 63.53% |
Vivesto AB | 355.87 Million SEK | 83.56% |